RARECast
En podcast av RARECast - Torsdagar
548 Avsnitt
-
Leveraging Technology to Empower Patients and Decentralize Clinical Trials
Publicerades: 2022-10-20 -
Equipping The Next-Generation Rare Disease Patient Advocate
Publicerades: 2022-10-13 -
How a Family Raced from Diagnosis to Experimental Gene Therapy in Three Years
Publicerades: 2022-10-06 -
How One Advocate Went from Losing His Hearing to Being Heard
Publicerades: 2022-09-29 -
Building a Pipeline of Therapies to Treat Rare Mineralization Disorders
Publicerades: 2022-09-22 -
Advancing an Oral Alternative to Infused and Injected Therapies for HAE
Publicerades: 2022-09-15 -
Embracing the Promise of Patient-Centered Biotechnology
Publicerades: 2022-09-08 -
Learning to Live with Loss
Publicerades: 2022-09-01 -
Using Cryptocurrency to Tap into the Wisdom of Crowds
Publicerades: 2022-08-25 -
A Therapy for a Rare Neurodegenerative Disease Moves Towards Regulatory Review
Publicerades: 2022-08-18 -
Transforming the Treatment of Neuromuscular Diseases with Next-Gen Oligonucleotides
Publicerades: 2022-08-11 -
Teaching the Immune System to Let Medicines Do Their Job
Publicerades: 2022-08-04 -
Designing Clinical Trials with the Patient in Mind
Publicerades: 2022-07-28 -
Keeping Clinical Trials Running Smoothly
Publicerades: 2022-07-21 -
A Vision for Patient-Centric Gene Therapy Development
Publicerades: 2022-07-14 -
Using Genetic Testing to Address Disparities in Care for Kidney Disease
Publicerades: 2022-07-07 -
Why Reforms to the Accelerated Approval Pathway Threaten Rare Disease Drug Development
Publicerades: 2022-06-30 -
A Longstanding Academic-Nonprofit Collaboration Gives Rise to an ALS Drug Company
Publicerades: 2022-06-16 -
Targeting Regulatory RNA to Upregulate Gene Expression to Treat Rare Diseases
Publicerades: 2022-06-09 -
Developing a New Approach to Treat Rare, Autoimmune Conditions
Publicerades: 2022-06-02
RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.
